 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Isentress |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a608004 |
| License data |
|
| Routes of administration | oral |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 60%(FDA) |
| Protein binding | 83% |
| Metabolism | Hepatic (UGT1A1) |
| Elimination half-life | 9 hours |
| Excretion | feces and urine |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C20H21FN6O5 |
| Molar mass | 444.423 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Raltegravir (RAL), sold under the brand name Isentress, is an antiretroviral medication used, together with other medication, to treat HIV/AIDS.[2] It may also be used, as part of post exposure prophylaxis, to prevent HIV infection following potential exposure.[3] It is taken by mouth.[2]
Common side effects include trouble sleeping, feeling tired, nausea, high blood sugar, and headaches.[3] Severe side effects may include allergic reactions including Stevens–Johnson syndrome, muscle breakdown, and liver problems.[3] It is unclear if use during pregnancy or breastfeeding is safe.[3] Raltegravir is an HIV integrase strand transfer inhibitor which blocks the functioning of HIV integrase which is needed for viral replication.[3]
Raltegravir was approved for medical use in the United States in 2007.[3] It is on the World Health Organization's List of Essential Medicines.[4] In the United Kingdom it costs the NHS about 472 pounds per month.[2] Lamivudine/raltegravir, a combination with lamivudine, is also available.[3]
References
edit- ^ Cite error: The named reference
whowas invoked but never defined (see the help page). - ^ a b c British national formulary : BNF 69 (69 ed.). British Medical Association. 2015. p. 429. ISBN 9780857111562.
- ^ a b c d e f g "Raltegravir Potassium". The American Society of Health-System Pharmacists. Archived from the original on 11 December 2017. Retrieved 8 December 2017.
- ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.